President and CMO at Achieve Life Sciences, Dr. Cindy Jacobs, spoke with Technology Networks about the key challenges related to breaking nicotine addiction and Achieve Life Sciences’ mission to help people who are looking to quit smoking.

Laura Elizabeth Lansdowne

Managing Editor

The pharmaceutical company Achieve Life Sciences is focused on addressing one of the biggest public health threats globally – tobacco use. By developing treatment options for people who are battling nicotine addiction, it hopes to reduce the number of preventable deaths caused by smoking.

Technology Networks had the pleasure of speaking with Cindy Jacobs, MD, PhD and chief medical officer at Achieve Life Sciences to learn more about cytisinicline, a plant-based alkaloid the company is currently developing as a smoking cessation treatment.

Laura Lansdowne (LL): Tobacco use is one of the biggest public health threats globally. Could you elaborate on the current global tobacco and nicotine addiction epidemic, what strategies can be used to address this?

Cindy Jacobs
 (CJ): Smoking is the number one cause of preventable death and is responsible for 8 million prematur